Aimmune Therapeutics (AIMT) Gets a Buy Rating from Wedbush

Wedbush analyst Liana Moussatos reiterated a Buy rating on Aimmune Therapeutics (AIMTResearch Report) today and set a price target of $79. The company’s shares closed yesterday at $21.16, close to its 52-week low of $19.25.

According to, Moussatos has currently no stars on a ranking scale of 0-5 stars, with an average return of -9.3% and a 33.3% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Aquestive Therapeutics Inc, and Allena Pharmaceuticals Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aimmune Therapeutics with a $51.14 average price target, a 141.7% upside from current levels. In a report issued on June 19, Piper Jaffray also maintained a Buy rating on the stock with a $60 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $36.12 and a one-year low of $19.25. Currently, Aimmune Therapeutics has an average volume of 483.8K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.